{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:03:17Z","timestamp":1790614997119,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T00:00:00Z","timestamp":1424044800000},"content-version":"vor","delay-in-days":898,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"crossref","award":["DK074835"],"award-info":[{"award-number":["DK074835"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Charles L. Edelstein.","award":["DK07483503S1"],"award-info":[{"award-number":["DK07483503S1"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","krcp-ksn.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Research and Clinical Practice"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.krcp.2012.07.002","type":"journal-article","created":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T21:22:15Z","timestamp":1344633735000},"page":"132-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside"],"prefix":"10.1016","volume":"31","author":[{"given":"Hyun-Jung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.krcp.2012.07.002_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199307293290508","article-title":"Autosomal dominant polycystic kidney disease","volume":"329","author":"Gabow","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2012.07.002_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.krcp.2012.07.002_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/13543781003588491","article-title":"Novel targets for the treatment of autosomal dominant polycystic kidney disease","volume":"19","author":"Belibi","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.krcp.2012.07.002_bib4","doi-asserted-by":"crossref","first-page":"c25","DOI":"10.1159\/000334166","article-title":"Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects","volume":"120","author":"Chang","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.krcp.2012.07.002_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMra022161","article-title":"Polycystic kidney disease","volume":"350","author":"Wilson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2012.07.002_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ki.1991.80","article-title":"C-myc as an inducer of polycystic kidney disease in transgenic mice","volume":"39","author":"Trudel","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2012.07.002_bib7","first-page":"1051","article-title":"Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys","volume":"142","author":"Schaffner","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.krcp.2012.07.002_bib8","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.krcp.2012.07.002_bib9","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","article-title":"Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases","volume":"5","author":"Torres","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2012.07.002_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ncb847","article-title":"Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling","volume":"4","author":"Gao","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.krcp.2012.07.002_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","article-title":"Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action","volume":"110","author":"Hara","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.krcp.2012.07.002_bib12","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1073\/pnas.95.4.1432","article-title":"RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1","volume":"95","author":"Burnett","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.krcp.2012.07.002_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1356-9597.2004.00727.x","article-title":"Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function","volume":"9","author":"Oshiro","year":"2004","journal-title":"Genes Cells"},{"key":"10.1016\/j.krcp.2012.07.002_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A complex interplay between Akt, TSC2 and the two mTOR complexes","volume":"37","author":"Huang","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.krcp.2012.07.002_bib15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.krcp.2012.07.002_bib16","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","article-title":"Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony","volume":"285","author":"Foster","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.krcp.2012.07.002_bib17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.krcp.2012.07.002_bib18","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/onc.2010.139","article-title":"Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy","volume":"29","author":"Sparks","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.krcp.2012.07.002_bib19","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood-2010-05-285726","article-title":"Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor","volume":"116","author":"Hoang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.krcp.2012.07.002_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.phrs.2007.04.001","article-title":"Classical PKC isoforms in cancer","volume":"55","author":"Martiny-Baron","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.krcp.2012.07.002_bib21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/ncb2117","article-title":"Primary cilia regulate mTORC1 activity and cell size through Lkb1","volume":"12","author":"Boehlke","year":"2010","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.krcp.2012.07.002_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1681\/ASN.2010050526","article-title":"Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis","volume":"22","author":"Bell","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2012.07.002_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000314380","article-title":"The mTOR pathway is activated in human autosomal-recessive polycystic kidney disease","volume":"33","author":"Becker","year":"2010","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.krcp.2012.07.002_bib24","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/ndt\/gfn744","article-title":"Activation of the AKT\/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD)","volume":"24","author":"Fischer","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2012.07.002_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD)","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2012.07.002_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2012.07.002_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.krcp.2012.07.002_bib28","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.krcp.2012.07.002_bib29","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/ndt\/gfp129","article-title":"Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)","volume":"24","author":"Zafar","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2012.07.002_bib30","doi-asserted-by":"crossref","first-page":"F236","DOI":"10.1152\/ajprenal.00129.2010","article-title":"mTORC1\/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease","volume":"300","author":"Belibi","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.krcp.2012.07.002_bib31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2012.07.002_bib32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.2010.250","article-title":"Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease","volume":"78","author":"Zafar","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2012.07.002_bib33","doi-asserted-by":"crossref","first-page":"F1597","DOI":"10.1152\/ajprenal.00430.2009","article-title":"Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease","volume":"297","author":"Wu","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.krcp.2012.07.002_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ndt\/gfq384","article-title":"Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats","volume":"26","author":"Renken","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2012.07.002_bib35","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2011040340","article-title":"Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease","volume":"23","author":"Novalic","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2012.07.002_bib36","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"106","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.krcp.2012.07.002_bib37","doi-asserted-by":"crossref","first-page":"F636","DOI":"10.1152\/ajprenal.00265.2011","article-title":"2-Hydroxyestradiol slows progression of experimental polycystic kidney disease","volume":"302","author":"Anderson","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.krcp.2012.07.002_bib38","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1172\/JCI41531","article-title":"Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease","volume":"120","author":"Qin","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.krcp.2012.07.002_bib39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2012.07.002_bib40","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2012.07.002_bib41","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.krcp.2012.07.002_bib42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.krcp.2012.07.002_bib43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJMe1006925","article-title":"mTOR inhibitors in polycystic kidney disease","volume":"363","author":"Watnick","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.krcp.2012.07.002_bib44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nrneph.2010.153","article-title":"Do mTOR inhibitors still have a future in ADPKD?","volume":"6","author":"Perico","year":"2010","journal-title":"Nar Rev Nephrol"},{"key":"10.1016\/j.krcp.2012.07.002_bib45","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Pallet N, Heyer CM, Letavernier E, Bienaim\u00e9 F, Thervet E, Martinez F, Terzi F, Legendre C: Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.krcp.2012.07.002_bib46","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1093\/ndt\/gfq527","article-title":"Autosomal dominant polycystic kidney disease and mTOR inhibitors:the narrow road between hope and disappointment","volume":"25","author":"Ponticelli","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2012.07.002_bib47","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4161\/cc.8.23.10070","article-title":"Targeting mTOR globally in cancer; thinking beyond rapamycin","volume":"8","author":"Shor","year":"2009","journal-title":"Cell Cycle"}],"container-title":["Kidney Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211913212007115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211913212007115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T14:59:55Z","timestamp":1542812395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211913212007115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S2211913212007115"],"URL":"https:\/\/doi.org\/10.1016\/j.krcp.2012.07.002","relation":{},"ISSN":["2211-9132"],"issn-type":[{"value":"2211-9132","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Kidney Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.krcp.2012.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Korea LLC.","name":"copyright","label":"Copyright"}]}}